CERVIX | CERVICAL SCREENING [ISSN 1804-087X]
česky | english | sitemap


PARTNERS AND EXPERT GUARANTEE
 
Czech Gynaecological and Obstetrical Society | Ministry of Health | Institute of Biostatistics and Analyses, Masaryk University
GRANT SUPPORT OF THE PROJECT
 
GlaxoSmithKline     Roche |

Other sources of information
Cervical cytology (in Czech)www.cipek.cz
Cervical cytology
 
Cancer Screening in the European Unionec.europa.eu
Cancer Screening in the European Union (2017)
[ 10,6 MB]
 
SVOD - Epidemiology of malignant tumours in the Czech Republicwww.svod.cz
Epidemiology of malignant tumours
in the Czech Republic
 
NCI Bethesda System
HPV College

 

Cervical cancer vaccine 'may prevent more cases than initially thought'

The cervical cancer vaccine could prevent even more cases of the disease in England than previously thought, UK scientists have found.


A study by scientists at the Health Protection Agency (HPA), the University of Manchester and the Manchester Royal Infirmary suggests that the vaccine could potentially reduce the number of cases each year from about 3,000 to less than 700.

Previous studies had suggested that about 70 per cent of cases of cervical cancer are caused by types 16 or 18 of the human papillomavirus (HPV) - against which the current cervical cancer vaccine provides protection.

Read the whole article at Cancer Research UK

Reference

  1. Howell-Jones, R. et al (2010). Multi-site study of HPV type-specific prevalence in women with cervical cancer, intraepithelial neoplasia and normal cytology, in England British Journal of Cancer, 103 (2), 209-216 DOI: 10.1038/sj.bjc.6605747

16.7.2010 Cancer Research UK


Back